Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 3.52
AVNR's Cash to Debt is ranked higher than
72% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. AVNR: 3.52 )
AVNR' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 3.52

Equity to Asset 0.56
AVNR's Equity to Asset is ranked higher than
64% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.61 vs. AVNR: 0.56 )
AVNR' s 10-Year Equity to Asset Range
Min: -0.16   Max: 0.95
Current: 0.56

-0.16
0.95
F-Score: 5
Z-Score: 4.46
M-Score: -1.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -94.77
AVNR's Operating margin (%) is ranked lower than
53% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. AVNR: -94.77 )
AVNR' s 10-Year Operating margin (%) Range
Min: -1373.1   Max: 35.08
Current: -94.77

-1373.1
35.08
Net-margin (%) -100.15
AVNR's Net-margin (%) is ranked lower than
53% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. AVNR: -100.15 )
AVNR' s 10-Year Net-margin (%) Range
Min: -1389.34   Max: 1.84
Current: -100.15

-1389.34
1.84
ROE (%) -408.60
AVNR's ROE (%) is ranked lower than
58% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. AVNR: -408.60 )
AVNR' s 10-Year ROE (%) Range
Min: -8600   Max: 0.97
Current: -408.6

-8600
0.97
ROA (%) -99.21
AVNR's ROA (%) is ranked lower than
57% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.09 vs. AVNR: -99.21 )
AVNR' s 10-Year ROA (%) Range
Min: -477.78   Max: 0.86
Current: -99.21

-477.78
0.86
ROC (Joel Greenblatt) (%) -4483.80
AVNR's ROC (Joel Greenblatt) (%) is ranked lower than
56% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.47 vs. AVNR: -4483.80 )
AVNR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7049.84   Max: 342.25
Current: -4483.8

-7049.84
342.25
Revenue Growth (%) 160.40
AVNR's Revenue Growth (%) is ranked higher than
99% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AVNR: 160.40 )
AVNR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 160.4
Current: 160.4

0
160.4
EBITDA Growth (%) 18.60
AVNR's EBITDA Growth (%) is ranked higher than
82% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. AVNR: 18.60 )
AVNR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 223.2
Current: 18.6

0
223.2
EPS Growth (%) 20.90
AVNR's EPS Growth (%) is ranked higher than
83% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. AVNR: 20.90 )
AVNR' s 10-Year EPS Growth (%) Range
Min: -67.9   Max: 238.4
Current: 20.9

-67.9
238.4
» AVNR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AVNR Guru Trades in Q1 2013

Steven Cohen Sold Out
» More
Q3 2013

AVNR Guru Trades in Q3 2013

Steven Cohen 14,500 sh (New)
Paul Tudor Jones 42,100 sh (New)
» More
Q4 2013

AVNR Guru Trades in Q4 2013

Steven Cohen 22,061 sh (+52.14%)
Paul Tudor Jones Sold Out
» More
Q1 2014

AVNR Guru Trades in Q1 2014

Steven Cohen 25,798 sh (+16.94%)
» More
» Details

Insider Trades

Latest Guru Trades with AVNR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.90
AVNR's P/B is ranked lower than
65% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.42 vs. AVNR: 13.90 )
AVNR' s 10-Year P/B Range
Min: 0.78   Max: 72.33
Current: 13.9

0.78
72.33
P/S 8.67
AVNR's P/S is ranked lower than
67% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.45 vs. AVNR: 8.67 )
AVNR' s 10-Year P/S Range
Min: 2.23   Max: 116.75
Current: 8.67

2.23
116.75
Current Ratio 3.06
AVNR's Current Ratio is ranked higher than
75% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. AVNR: 3.06 )
AVNR' s 10-Year Current Ratio Range
Min: 0.35   Max: 22.13
Current: 3.06

0.35
22.13
Quick Ratio 3.04
AVNR's Quick Ratio is ranked higher than
80% of the 560 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. AVNR: 3.04 )
AVNR' s 10-Year Quick Ratio Range
Min: 0.29   Max: 22.13
Current: 3.04

0.29
22.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 27.70
AVNR's Price/Net Cash is ranked higher than
83% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AVNR: 27.70 )
AVNR' s 10-Year Price/Net Cash Range
Min: 1.64   Max: 333.33
Current: 27.7

1.64
333.33
Price/Net Current Asset Value 18.20
AVNR's Price/Net Current Asset Value is ranked higher than
78% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AVNR: 18.20 )
AVNR' s 10-Year Price/Net Current Asset Value Range
Min: 1.64   Max: 250
Current: 18.2

1.64
250
Price/Tangible Book 13.80
AVNR's Price/Tangible Book is ranked lower than
63% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. AVNR: 13.80 )
AVNR' s 10-Year Price/Tangible Book Range
Min: 1.12   Max: 90.91
Current: 13.8

1.12
90.91
Price/Median PS Value 0.70
AVNR's Price/Median PS Value is ranked higher than
93% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. AVNR: 0.70 )
AVNR' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 55.56
Current: 0.7

0.11
55.56
Earnings Yield (Greenblatt) 0.40
AVNR's Earnings Yield (Greenblatt) is ranked lower than
64% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. AVNR: 0.40 )
AVNR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 3.8
Current: 0.4

0.4
3.8
Forward Rate of Return (Yacktman) 0.49
AVNR's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. AVNR: 0.49 )
AVNR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -0.5
Current: 0.49

-1.8
-0.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:AV2B.Germany
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a pharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an innovative combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.
» More Articles for AVNR

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 
Avanir Pharmaceuticals Reports Operating Results (10-Q) Aug 05 2010 
Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 105,906 Shares May 04 2010 


More From Other Websites
AVANIR PHARMACEUTICALS, INC. Financials Aug 15 2014
AVANIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 07 2014
Avanir's Q3 Loss in Line, Revenues Up on High Nuedexta Demand Aug 06 2014
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update Aug 05 2014
Avanir Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 05 2014
AVANIR PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 05 2014
Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update Aug 05 2014
Avanir Pharmaceuticals to Participate in Two Conferences in August Aug 05 2014
Avanir Pharmaceuticals to Participate in Two Conferences in August Aug 05 2014
Q3 2014 Avanir Pharmaceuticals Earnings Release - After Market Close Aug 05 2014
Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference... Jul 28 2014
Avanir Pharmaceuticals Announces Date of Fiscal 2014 Third Quarter Financial Results and Conference... Jul 28 2014
Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of... Jul 21 2014
Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of... Jul 21 2014
Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study Jul 16 2014
Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study Jul 16 2014
3 Biotech Stocks Under $10 to Trade for Breakouts Jul 11 2014
Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Jul 09 2014
Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the... Jun 30 2014
Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the... Jun 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide